2021 · van Gelder et al. — Safety of Electrooxidation for Urea Removal in a Wearable Artificial Kidney Is Compromised by Formation of Glucose Degradation Products
Super-Abstract
A wearable artificial kidney (WAK) using electrooxidation to destroy urea in dialysate generates dangerous glucose degradation products — making the current approach unsafe for clinical use. Hydrogen gas is a byproduct of the electrooxidation process, not a therapeutic intervention. This is an in-vitro safety engineering study with no relevance to biomedical hydrogen therapy.
Commentary
The wearable artificial kidney is a long-sought technology to free dialysis patients from thrice-weekly clinic sessions. One major challenge is urea removal from spent dialysate. Electrooxidation (EO) applies electric current to convert urea into nitrogen, carbon dioxide, and hydrogen gas. This study found that EO simultaneously generates highly toxic glucose degradation products (GDPs) — glyoxal, methylglyoxal, and 3-deoxyglucosone — at dramatically elevated concentrations (up to 353-fold above baseline in peritoneal effluent). These GDPs are not biocompatible and would cause severe harm if returned to the patient. Hydrogen gas appears here purely as an unwanted byproduct of the electrochemical urea conversion process, not as a therapeutic molecule. This paper has no relevance to hydrogen water, H₂ inhalation therapy, or any therapeutic use of molecular hydrogen. It belongs to nephrology engineering safety literature.
Key quotes
- „Glyoxal and methylglyoxal concentrations increased 26- and 11-fold, respectively, in uremic plasma and 209- and 353-fold, respectively, in peritoneal effluent during treatment with EO.“ — the safety finding: massive GDP generation makes electrooxidation currently unsuitable
- „EO for dialysate regeneration in a WAK is currently not safe due to the generation of GDPs which are not biocompatible.“ — the clear conclusion: electrooxidation is not yet a viable approach for wearable dialysis
Our assessment
This study is not relevant to biomedical hydrogen therapy. Hydrogen gas is generated as an incidental byproduct of an electrochemical urea conversion process in a dialysis engineering experiment. The paper contributes to the wearable artificial kidney literature by identifying a critical safety barrier for electrooxidation. It should not be cited in any context related to therapeutic molecular hydrogen.
Study design
- Type: in-vitro safety study (dialysis engineering) · n: uremic plasma and peritoneal effluent samples treated for 8 hours · H₂ role: byproduct of electrooxidation — not therapeutic
- Primary concern: glucose degradation products (glyoxal, methylglyoxal, 3-deoxyglucosone) · Result: 11–353-fold GDP increase during EO; electrooxidation declared currently unsafe for WAK application
Abstract
A major challenge for the development of a wearable artificial kidney (WAK) is the removal of urea from the spent dialysate, as urea is the waste solute with the highest daily molar production and is difficult to adsorb. Here we present results on glucose degradation products (GDPs) formed during electrooxidation (EO), a technique that applies a current to the dialysate to convert urea into nitrogen, carbon dioxide, and hydrogen gas. Uremic plasma and peritoneal effluent were dialyzed for 8 hours with a WAK with and without EO-based dialysate regeneration. Samples were taken regularly during treatment. GDPs (glyoxal, methylglyoxal, and 3-deoxyglucosone) were measured in EO- and non-EO-treated fluids. Glyoxal and methylglyoxal concentrations increased 26- and 11-fold, respectively, in uremic plasma (at [glucose] 7 mmol/L) and 209- and 353-fold, respectively, in peritoneal effluent (at [glucose] 100 mmol/L) during treatment with EO, whereas no change was observed in GDP concentrations during dialysate regeneration without EO. EO for dialysate regeneration in a WAK is currently not safe due to the generation of GDPs which are not biocompatible.
Source & links
Screenshot of the PubMed page
This page mirrors the published abstract (© the authors / publisher) for reference and citation. The canonical source is the PubMed record linked above. This is not medical advice.